Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Isatuximab + pomalidomide + dexamethasone for previously treated AL amyloidosis
ACTRN12621001530819Phase 2Completed
- Sponsor
- Inter-Groupe Francophone du Myélome
- Start
- May 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of isatuximab, pomalidomide and dexamethasone in light-chain amyloidosis, sponsored by Inter-Groupe Francophone du Myélome. Primary endpoint: Hematologic response rate (VGPR or better) after 6 cycles. Started May 2022; status: completed.
02
Drugs
isatuximabpomalidomidedexamethasone
03
Conditions
light-chain amyloidosis
Beyond the preview
Go deeper on ACTRN12621001530819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12621001530819.